secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001193125-24-223676
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals amends manufacturing agreement with Renaissance Lakewood for neffy nasal spray
--------------------------------------------------------------------------------

- Second amendment to manufacturing agreement for neffy executed September 17, 2024.
- Initial term extended to five years after U.S. commercial launch and five years after EU launch, with automatic two-year renewals.
- Termination provisions revised for breach, insolvency, regulatory denial/withdrawal, force majeure, and trade law violations.
- Agreement covers neffy (epinephrine nasal spray) for anaphylaxis treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524223676/0001193125-24-223676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524223676/d834306d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-223676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer